ZyVac TCV

ZyVac® TCV — WHO endorsed shield against typhoid

ZyVac TCV is a Typhoid Vi Conjugate Vaccine (Vi-TT) developed and manufactured by Zydus Lifesciences. It provides active immunization against typhoid fever caused by Salmonella typhi. The vaccine is WHO prequalified and is a Made-in-India solution to combat typhoid in endemic regions. ZyVac TCV is the world’s second fully indigenously developed Typhoid Conjugate Vaccine.

Key Features
  • Conjugate Technology: Contains 25 μg of purified Vi-capsular polysaccharide of Salmonella typhi chemically conjugated to tetanus toxoid as a carrier protein. This T-cell dependent response offers superior and longer-lasting immunity compared to older polysaccharide vaccines, especially in young children.
  • Broad Age Coverage: Indicated for active immunization in individuals from 6 months to 65 years of age.
  • High Immunogenicity: Clinical trials have demonstrated strong seroconversion rates, and persistence of immunity up to 3 years post-vaccination.
Target Population

ZyVac TCV is particularly recommended for:

  • Infants and young children (from 6 months of age)
  • Adult and elderly people up to 65 years of age
  • Residents in typhoid-endemic areas
  • Travelers to high-risk regions
  • Individuals with increased exposure risk, such as healthcare workers or those in outbreak settings
Administration
  • Dose: Each Single dose of 0.5 ml should be given intramuscularly in the deltoid or the vastus lateralis of children below two years of age
  • Schedule: One primary dose provides protection starting 2–3 weeks after immunization. A booster dose may be administered after 3 years for individuals who remain at continued risk.
Presentations:

Approved in three presentations.

  • Single dose pre-filled syringe
  • Single dose vial
  • Multi-dose vials (2.5ml- 5-dose): Supplied with VVM 30

Once opened, multi dose vials can be used in subsequent immunization sessions for up to a maximum of 28 days as per open vial policy.

Safety and Efficacy

ZyVac TCV has been evaluated in multiple clinical trials (Phase I to IV) and post-marketing surveillance involving thousands of participants across all indicated age groups, including co-administration studies with measles-rubella vaccine and also yellow fever vaccine. It demonstrated a favourable safety profile with high immunogenicity and was well tolerated. Common side effects are mild and transient, such as injection site pain, redness, swelling, or low-grade fever. Serious adverse events are rare.

As a reliable, WHO-prequalified Typhoid Vi conjugate vaccine, ZyVac TCV supports public health efforts to reduce the burden of typhoid fever, particularly in children and at-risk populations. Vaccination strategies should align with local epidemiology and national immunization guidelines.

Publications
  • Kundu R, Kandulna AK, Nayak U, Jangid SK, Babu TR, Vukkala R, Sharma S, Goyal VK, Daultani P, Mittal R, Patel P. Immunogenicity and Safety of Typhoid Conjugate Vaccine in Healthy Indian Subjects: A Randomized, Active-controlled, Comparative Clinical Trial. Indian Pediatr. 2020 Jul 15;57(7):625-630. PMID: 32727938.
  • Kandulna AK, Uttam KG, Sharma S, Kumar MR, Prasad KS, Goyal VK, Jangid SK, Daultani P, Mittal R, Maithal K. Long-term Persistence of Immunogenicity After Primary Vaccination and Response to Booster Vaccination With Typhoid Conjugate Vaccine: Results of a Phase IV Extension Study. Indian Pediatr. 2022 May 15;59(5):388-392. Epub 2022 Mar 28. PMID: 35348124.
  • Mankar SV, Patel C, Chavan A, Modi R, Sarangi L, Tripathi VN, Dash DK, Narayan JP, Bandgar S, Kumar NR, Gill VK, Kakkar MK, Mitra M, Daultani P, Mittal R, Maithal K, Kansagra K, Parmar DV, Dutta T, Mahajan M, Desai S. An active post-marketing surveillance study to evaluate the safety and immunogenicity of Zyvac TCV in healthy participants. Hum Vaccin Immunother. 2025 Dec;21(1):2550085. doi: 10.1080/21645515.2025.2550085. Epub 2025 Aug 26. PMID: 40855908; PMCID: PMC12382467.
  • Rao SN, Ambike D, Patil M, Mankar SV, Verma N, Hanumante N, Sarangi L, Mitra M, Preeti G, Deshmukh BJ, Nanoti G, Faridi MMA, Daultani P, Mittal R, Maithal K, Kansagra K, Parmar DV, Kunnathamman R, Elaiyaraja M, Dutta T, Mahajan M, Desai S. Immunogenicity and Safety Results of a Randomized, Three-Arm, Phase IV Clinical Trial of Concomitant Administration of Typhoid Vi Conjugate Vaccine with Measles and Rubella Vaccine in Healthy Infants. Viruses. 2025 Sep 12;17(9):1237. doi: 10.3390/v17091237. PMID: 41012665; PMCID: PMC12474091.